MedTrace Logo

Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NCT01128426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53902

Last updated 2014-07-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.

Conditions

  • Pneumococcal Disease

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
2 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128426 on ClinicalTrials.gov